Segment Reporting (Summary of Net Revenues by Product Segment) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	$ 85,806	$ 79,047	$ 170,494	$ 158,837
Finished Pharmaceutical Products
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	80,935	73,735	162,233	148,274
Finished Pharmaceutical Products | Enoxaparin
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	10,218	9,838	19,386	24,322
Finished Pharmaceutical Products | Lidocaine
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	7,608	10,082	18,265	22,061
Finished Pharmaceutical Products | Phytonadione
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	10,689	12,441	21,718	22,561
Finished Pharmaceutical Products | Naloxone
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	8,723	7,833	17,598	15,197
Finished Pharmaceutical Products | Epinephrine
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	6,957	3,139	10,947	5,818
Finished Pharmaceutical Products | Primatene Mist
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	12,468	2,512	25,345	5,409
Finished Pharmaceutical Products | Other Finished Pharmaceutical Products
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	$ 24,272	$ 27,890	$ 48,974	$ 52,906